Front Med (Lausanne). 2026 Sep 16;13:1890483. doi: 10.3389/fmed.2026.1890483. eCollection 2026.
ABSTRACT
Progressive retinal neurodegeneration remains a major therapeutic challenge in ophthalmology because structural and functional loss may continue despite control of the primary insult, including intraocular pressure reduction in glaucoma, metabolic management in diabetic retinopathy, or suppression of acute inflammatory activity. Ferroptosis, an iron-dependent form of regulated cell death driven by phospholipid peroxidation and insufficient antioxidant buffering, has emerged as a potential mechanism linking metabolic stress, ischemic injury, excitotoxicity, and neuroinflammatory signaling to sustained retinal neurovascular unit damage. In this review, we synthesize current evidence supporting ferroptosis-related vulnerability in retinal neurodegenerative diseases. Particular emphasis is placed on expansion of the labile iron pool, PUFA-phospholipid remodeling, dysfunction of the System Xc⁻/glutathione (GSH)/glutathione peroxidase 4 (GPX4) axis, and multicellular amplification within the neuro-glial-microvascular unit. We further compare disease-specific evidence in glaucoma, diabetic retinopathy, and selected optic nerve injury contexts, emphasizing that causal validation remains uneven across models, cell types, and disease stages. From a translational perspective, we discuss why anti-ferroptotic strategies face distinct ophthalmic barriers, including limited retinal access, insufficient local exposure, short intraocular residence, and safety constraints associated with chronic modulation of iron and redox metabolism. Finally, we evaluate emerging enabling strategies, including nanocarrier-based delivery, long-acting gene modulation, and biomarker frameworks integrating ocular fluids, imaging, multi-omics, and artificial intelligence. Ferroptosis-targeted neuroprotection is therefore best viewed as a disease- and stage-dependent translational framework rather than a universal therapeutic solution.
PMID:42819585 | PMC:PMC13624404 | DOI:10.3389/fmed.2026.1890483